Sotera Health posts Q3 2026 earnings beat and reaffirms 2026 outlook amid European demand softness

Sotera Health reported third‑quarter 2026 adjusted earnings of $0.29 per share on revenue of $324.9 million, beating expectations. Revenue grew 4.4% on a constant‑currency basis and adjusted EBITDA rose 4% to $171 million, with the margin expanding to 52.5%. Management highlighted softening medical‑device demand in Europe, flat Sterigenics revenue expected for Q4, and reaffirmed its 2026 revenue and adjusted EBITDA growth targets.

The company’s reaffirmation of 2026 revenue growth of 5.25%‑6.75% and adjusted EBITDA growth of 5.75%‑7.25% signals continued upside potential for investors. Net leverage improved to 2.9x, within the 2.0‑3.0x target range, supporting a recent Moody’s credit rating upgrade.

Sources